Codeine-based cough syrup and NDPS exemption: lack of therapeutic use can attract the narcotics regime, while bail still depends on independent evidence.

Codeine-based cough syrup may fall within the NDPS regime as a manufactured drug or essential narcotic drug when its possession or transport is not shown to be for therapeutic use, and the stated dosage-based exemption will not apply without supporting documents. The material and rules governing essential narcotic drugs regulate possession and transport within the prescribed framework. For bail under the NDPS Act, the Court noted that a co-accused's memorandum and call detail records, without independent incriminating recovery from the applicant, were insufficient to satisfy the Section 37 bar. On that material, the applicant was found entitled to bail.

---

---

Issues: (i) Whether cough syrup containing codeine, in the absence of proof of therapeutic use, falls within the NDPS regime as a manufactured drug or essential narcotic drug and attracts the penal provisions of the NDPS Act; (ii) Whether the material collected against the applicant justified rejection of bail under Section 37 of the NDPS Act.

Issue (i): Whether cough syrup containing codeine, in the absence of proof of therapeutic use, falls within the NDPS regime as a manufactured drug or essential narcotic drug and attracts the penal provisions of the NDPS Act.

Analysis: Codeine is treated as an opium derivative and the relevant notifications under the NDPS Act bring methyl morphine and its preparations within the category of manufactured drugs, subject to the exception for preparations containing not more than 100 milligrams per dosage unit and not more than 2.5% concentration in undivided preparations established in therapeutic practice. The later notification governing essential narcotic drugs and the corresponding rules regulate possession and transport only in accordance with the prescribed framework. In the absence of documents showing therapeutic purpose, possession or transport of a large quantity of codeine-based cough syrup cannot claim the exemption merely because the preparation contains a prescribed dosage quantity.

Conclusion: The syrup-based preparation, when carried without proof of therapeutic use, is covered by the NDPS regime and the exemption was not available.

Issue (ii): Whether the material collected against the applicant justified rejection of bail under Section 37 of the NDPS Act.

Analysis: The case against the applicant rested mainly on the co-accused's memorandum and call detail records, while nothing was recovered from the applicant's possession. The Court held that the co-accused's memorandum by itself was not admissible against the applicant without independent incriminating material. On the material available, the Court found no reasonable ground to hold that the applicant had committed the offence or that he would indulge in NDPS offences if enlarged on bail.

Conclusion: Bail was granted as the stringent bar under Section 37 was not found to be attracted against the applicant on the existing material.

Final Conclusion: The applicant was found entitled to bail because the evidence against him was not sufficient to justify continued custody, even though the seized cough syrup itself was treated as falling within the NDPS framework in the absence of proof of therapeutic use.

Ratio Decidendi: Codeine-based cough syrup loses the benefit of exemption when its possession or transport is not shown to be for therapeutic practice, and bail under the NDPS Act may still be granted where the applicant is not linked by independent incriminating evidence and the statutory bar is not satisfied on the available material.

---